This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a randomised, prospective, open-label, parallel trial that was carried out in several general practices in the UK and the Republic of Ireland. However, only patients enrolled in the UK were included in the analysis. The method of randomisation was not reported. The patients were followed for 12 weeks and assessment took place at weeks 4, 8 and 12. Four patients were lost to follow-up.
Analysis of effectiveness
The basis for the analysis was intention to treat. Patients who withdrew early through lack of effect or an adverse event were considered as failures. The primary health outcome assessed in the effectiveness analysis was the percentage of symptom-free days with no short-acting beta2-agonists. This was defined as days on which both the day-and nighttime symptom scores were recorded as zero, no nocturnal awakenings due to asthma were recorded, and short-acting beta2-agonist use was recorded at zero. The study groups were shown to be comparable at baseline, but there was a higher proportion of males in the eformoterol group than in the salmeterol group.
Effectiveness results
The mean percentage of symptom-free days with no short-acting beta2-agonists was 39% in the eformoterol group and 30% in the salmeterol group.
Clinical conclusions
The eformoterol-based treatment was more effective than the salmeterol therapy in increasing the number of symptomfree days.
Outcomes assessed in the review
The health outcomes used in the budget impact analysis were: the percentage of the population aged 6 to 17 years, the prevalence of Step 3 asthma in children aged 6 to 17 years according to the British Thoracic Society (entry criteria for the trial), the average GP practice list size and the number of eligible children, the average PCG population and the number of eligible children, and the average HA population and the number of eligible children.
Study designs and other criteria for inclusion in the review
Most of the primary studies were official statistics published in the UK.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
